Gastroparesis – Medxy AI

Metopimazine Mesylate (NG101) for Gastroparesis: Evaluating the Gap Between Patient Global Impression and Symptom Severity Scores

By MedXY 02/04/2026

A Phase 2 trial of NG101 for gastroparesis missed its primary endpoint for nausea severity on the DIGS-DD scale but demonstrated significant improvements in Patient Global Impression of Change (PGIC) and a favorable safety profile, particularly in idiopathic cases.

Gastroenterology news

Metopimazine Mesylate (NG101) in Gastroparesis: Navigating the Complexities of Nausea Management and Trial Endpoints

By MedXY 02/03/2026

This Phase 2 trial of NG101 for gastroparesis did not meet its primary endpoint for nausea severity reduction but showed significant global improvement in patient-reported outcomes and a favorable safety profile, particularly in idiopathic cases.

Gastroenterology Internal Medicine news

A Glimmer of Hope for the ‘Slow Stomach’: Exploring the New Frontier in Gastroparesis Treatment

By MedXY 02/03/2026

This article examines the Phase 2 trial of NG101 (metopimazine), a novel treatment for gastroparesis. While the primary endpoint was missed, significant improvements in patient-reported outcomes and a strong safety profile suggest a potential breakthrough for those with idiopathic gastroparesis.

$Combined Gastric Electrical Stimulation and Pyloroplasty Achieve Superior Symptom Relief in Refractory Gastroparesis$

Gastroenterology General Surgery news

Combined Gastric Electrical Stimulation and Pyloroplasty Achieve Superior Symptom Relief in Refractory Gastroparesis

By MedXY 12/21/2025

A randomized clinical trial demonstrates that combining gastric electrical stimulation with pyloroplasty significantly outperforms pyloroplasty alone, providing superior symptom relief and reducing hospitalizations for patients with medication-refractory gastroparesis.